Scott Galloway warned of market shifts due to obesity and noted Eli Lilly is gaining FDA approval for weight management.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Scott Galloway warned of market shifts due to obesity and noted Eli Lilly is gaining FDA approval for weight management.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Scott Galloway
Professor of Marketing at NYU Stern School of Business, public speaker and entrepreneur
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- The FDA is ending compounding grace periods as competition intensifies and Lilly faces pipeline setbacks in the GLP-1 market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.